Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L K Newby

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
American Heart Journal|July 30, 1999
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering CommitteeL K Newby
American Heart Journal|August 31, 2000
Cardiac marker testing: where should we focus?L K Newby
American Heart Journal|June 30, 2001
The emerging role of myoglobin for risk stratificationL K Newby
Current Cardiology Reports|September 12, 2000
Oral platelet glycoprotein IIb/IIIa inhibitionL K Newby, D K McGuire
European Heart Journal|April 27, 2000
Troponins in pericarditis: implications for diagnosis and management of chest pains patientsL K Newby, E M Ohman
The American Journal of Cardiology|December 19, 1996
How much do we gain by reducing time to reperfusion therapy?R M Califf, L K Newby
Journal of Thrombosis and Thrombolysis|September 27, 2000
Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trialD K McGuire, L K Newby
The New England Journal of Medicine|December 24, 1998
The chest-pain unit--ready for prime time?L K Newby, D B Mark
Maryland Medical Journal (Baltimore, Md. : 1985)|January 1, 1997
Cardiac markers in the assessment of acute coronary syndromesR H Christenson, L K Newby, E M Ohman
The Journal of Clinical Investigation|May 1, 1993
Alternative splicing: a mechanism for phenotypic rescue of a common inherited defectH Morisaki, T Morisaki, L K Newby, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
American Heart Journal|July 30, 1999
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering CommitteeL K Newby
American Heart Journal|August 31, 2000
Cardiac marker testing: where should we focus?L K Newby
American Heart Journal|June 30, 2001
The emerging role of myoglobin for risk stratificationL K Newby
Current Cardiology Reports|September 12, 2000
Oral platelet glycoprotein IIb/IIIa inhibitionL K Newby, D K McGuire
European Heart Journal|April 27, 2000
Troponins in pericarditis: implications for diagnosis and management of chest pains patientsL K Newby, E M Ohman
The American Journal of Cardiology|December 19, 1996
How much do we gain by reducing time to reperfusion therapy?R M Califf, L K Newby
Journal of Thrombosis and Thrombolysis|September 27, 2000
Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trialD K McGuire, L K Newby
The New England Journal of Medicine|December 24, 1998
The chest-pain unit--ready for prime time?L K Newby, D B Mark
Maryland Medical Journal (Baltimore, Md. : 1985)|January 1, 1997
Cardiac markers in the assessment of acute coronary syndromesR H Christenson, L K Newby, E M Ohman
The Journal of Clinical Investigation|May 1, 1993
Alternative splicing: a mechanism for phenotypic rescue of a common inherited defectH Morisaki, T Morisaki, L K Newby, et al.
Pageof 4